SeaStar Medical Holding Corporation (ICU)

NASDAQ: ICU · IEX Real-Time Price · USD
0.717
-0.002 (-0.28%)
At close: Apr 12, 2024, 4:00 PM
0.720
+0.003 (0.42%)
After-hours: Apr 12, 2024, 7:59 PM EDT
-0.28%
Market Cap 46.71M
Revenue (ttm) n/a
Net Income (ttm) -35.57M
Shares Out 65.15M
EPS (ttm) -3.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,246,612
Open 0.729
Previous Close 0.719
Day's Range 0.685 - 0.800
52-Week Range 0.162 - 2.500
Beta -1.15
Analysts Strong Buy
Price Target 5.00 (+597.35%)
Earnings Date May 13, 2024

About ICU

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Co... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ICU
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ICU stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target
$5.0
(597.35% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU

NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investors...

1 day ago - PRNewsWire

SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference

DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of h...

2 days ago - GlobeNewsWire

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercia...

17 days ago - GlobeNewsWire

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company...

4 weeks ago - GlobeNewsWire

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

March 13 webcast showcasing Quelimmune ™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com

4 weeks ago - GlobeNewsWire

Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients

6 weeks ago - GlobeNewsWire

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SCD-PED (Pediatric) is the first FDA-approved product in the Company's Quelimmune™ product family

7 weeks ago - GlobeNewsWire

ICU stock price: Here's why SeaStar Medical shares have surged

SeaStar Medical Holding (NASDAQ: ICU) stock price has done well this year even as the company continued diluting its shareholders. The stock is about to hit $1, meaning that it has surged by more than...

2 months ago - Invezz

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

2 months ago - GlobeNewsWire

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of...

2 months ago - GlobeNewsWire

SeaStar Medical Appoints David A. Green as Chief Financial Officer

DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

3 months ago - GlobeNewsWire

SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications

DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

3 months ago - GlobeNewsWire

SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

DENVER, Dec. 28, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

3 months ago - GlobeNewsWire

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts

DENVER, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...

4 months ago - GlobeNewsWire

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce th...

5 months ago - GlobeNewsWire

FDA Issues Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric Patients

DENVER, Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...

5 months ago - GlobeNewsWire

SeaStar Medical's stock more than doubles in 2 days to get back above the $1 level

Shares of SeaStar Medical Holding Corp. ICU, +70.05% rocketed 45.3% on heavy volume in premarket trading Thursday, to take them back above the $1 mark for the first time in five months. Trading volume...

6 months ago - Market Watch

FDA Grants SeaStar Medical's Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

6 months ago - GlobeNewsWire

SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023

DENVER, Oct. 05, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

6 months ago - GlobeNewsWire

SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

Com pany to finalize labeling with FDA Approv able Letter expected within a month

6 months ago - GlobeNewsWire

FDA Grants Breakthrough Device Designation to SeaStar Medical's Selective Cytopheretic Device for Cardiorenal Syndrome

DENVER, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...

7 months ago - GlobeNewsWire

SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time

DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce th...

8 months ago - GlobeNewsWire

SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update

Management to hold a b usiness u pdate c onference c all on August 2 2 beginning at 4 :00 p.m. Eastern time

8 months ago - GlobeNewsWire

SeaStar Medical to Sponsor the Critical Care Time Podcast Series Covering Vital Medical Issues for Healthcare Professionals Who Care for Critically Ill Patients

DENVER, June 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

10 months ago - GlobeNewsWire

First Patient Enrolled in SeaStar Medical's Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

DENVER, June 20, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...

10 months ago - GlobeNewsWire